Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;37(8):1446-1454.
doi: 10.1111/jgh.15930. Epub 2022 Jul 7.

Patient-derived cancer organoids for drug screening: Basic technology and clinical application

Xiaoxue Ren  1   2 , Weikang Chen  2 , Qingxia Yang  1   2 , Xiaoxing Li  2 , Lixia Xu  1   2
Affiliations
Review

Patient-derived cancer organoids for drug screening: Basic technology and clinical application

Xiaoxue Ren et al. J Gastroenterol Hepatol. 2022 Aug.

Abstract

Cancer organoids, a three-dimensional (3D) culture system of cancer cells derived from tumor tissues, recapitulate physiological structure of the parental tumor. Different tumor organoids have been established for a variety of tumor types, such as colorectal, liver, stomach, pancreatic and brain tumors. Some tumor organoid biobanks are built to screen and discover novel antitumor drug targets. Moreover, patients-derived tumor organoids (PDOs) could predict treatment response to chemoradiotherapy, targeted therapy and immunotherapy to provide guidance for personalized cancer therapy. In this review, we provide an updated overview of tumor organoid development, summarize general approach to establish tumor organoids, and discuss the application of anti-cancer drug screening based on tumor organoid and its application in personalized therapy. We also outline the opportunities and challenges for organoids to guide precision medicine.

Keywords: cancer organoids; drug screening; precision medicine.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021; 71: 7-33.
    1. McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 2017; 168: 613-628.
    1. Fan H, Demirci U, Chen P. Emerging organoid models: leaping forward in cancer research. J. Hematol. Oncol. 2019; 12: 142.
    1. Drost J, Clevers H. Organoids in cancer research. Nat. Rev. Cancer 2018; 18: 407-418.
    1. Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J. Hematol. Oncol. 2018; 11: 116.

Substances

LinkOut - more resources